[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) – Form 4 insider purchase

On 17 and 18 June 2025, 10% shareholder Richard Ian Griffiths disclosed open-market purchases totaling 70,448 American Depositary Shares (ADS), coded “P”. The transactions were executed at $5.29 and $5.69 per ADS, representing an estimated cash outlay of roughly $0.39 million.

Because each ADS is immediately convertible into three ordinary shares at no additional cost, the buys expand Griffiths’ economic exposure by about 211,344 ordinary shares. His directly held ADS position rose from 11,392,779 to 11,431,828.

The filing did not reference a Rule 10b5-1 trading plan, suggesting discretionary purchases. No insider sales or derivative exercises were reported.

For investors, clustered insider buying by a large, long-tenured holder often serves as a constructive sentiment indicator, especially when executed near multi-year lows (price context not specified in the filing). While modest relative to Griffiths’ total stake, the fresh capital deployment may signal confidence in Silence Therapeutics’ valuation and forthcoming catalysts.

Insights

Securities Analyst

TL;DR: 10% owner adds $0.39 m in SLN ADS, lifting stake; insider confidence, mildly bullish.

Griffiths’ two-day accumulation of 70,448 ADS increases his holding by roughly 0.6%. Although the dollar size is small versus a >11 m-ADS base, purchases by a control-level shareholder are statistically correlated with above-market returns when clustered and unaccompanied by sales. The $5.29-$5.69 range is below prior financing levels, hinting at perceived undervaluation. Given Silence’s cash-intensive RNAi pipeline, insider capital commitment provides a positive behavioural signal but is unlikely to alter near-term liquidity or fundamental forecasts.

Corporate Governance Expert

TL;DR: Clean Form 4, discretionary buys, no governance red flags.

The filing shows proper Section 16 compliance and manual signature. The absence of a 10b5-1 checkbox indicates voluntary market purchases, generally viewed favourably from an alignment standpoint. No complex derivative structures were used and there is full conversion transparency (1 ADS = 3 ordinary shares). While the transaction size is not material to ownership control, it reinforces aligned incentives between management, major shareholders and public investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

FLOOR 1 LIBERATION STATION

ESPLANADE

(Street)

ST HELIER Y9 JE2 3AS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$5.29	06/17/2025		P		31,399		(1)	(1)	Ordinary Shares	94,197	(1)	11,392,779	D
American Depositary Shares	$5.69	06/18/2025		P		39,049		(1)	(1)	Ordinary Shares	117,147	(1)	11,431,828	D

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

	/s/ Richard Ian Griffiths	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.